Anticancer Properties of Distinct Antimalarial Drug Classes

• Rob Hooft van Huijsduijnen,

  Affiliation Medicines for Malaria Venture (MMV), Geneva, Switzerland

  ⨯
• R. Kiplin Guy,

  Affiliation St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America

  ⨯
• Kelly Chibale,

  Affiliation Department of Chemistry and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch, South Africa

  ⨯
• Richard K. Haynes,

  Affiliation Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa

  ⨯
• Ingmar Peitz,

  Affiliation Oncotest GmbH, Freiburg, Germany

  ⨯
• Gerhard Kelter,

  Affiliation Oncotest GmbH, Freiburg, Germany

  ⨯
• Margaret A. Phillips,

  Affiliation Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America

  ⨯
• Jonathan L. Vennerstrom,

  Affiliation Department of Pharmaceutical Sciences, Nebraska Medical Center, Omaha, Nebraska, United States of America

  ⨯
• Yongyuth Yuthavong,

  Affiliation BIOTEC, National Science and Technology Development Agency, Thailand Science Park, Pathumthani, Thailand

  ⨯
• Timothy N. C. Wells

  * E-mail: wellst@mmv.org

  Affiliation Medicines for Malaria Venture (MMV), Geneva, Switzerland

  ⨯